- A denial isn't final — 39-65% of insurance appeals succeed (across all insurance appeals, not Wegovy-specific)
- Most patients don't know they can appeal, but it's your legal right
- Understanding why you were denied is the first step to a successful appeal
- PEAK handles documentation, peer-to-peer reviews, and appeals on your behalf
You did everything right. You met with your doctor, submitted the prior authorization paperwork, waited for the decision — and your insurance said no.
It's frustrating. It feels unfair. And most people assume that's the end of the road.
It's not.
You have the legal right to appeal any insurance denial. And the data shows that appeals work: studies from the US Government Accountability Office found that 39-59% of internal appeals are successful. Some sources report success rates as high as 65% when appeals include strong supporting documentation.
The problem? Most people never try. One study found that 69% of patients who were denied coverage didn't even know they could appeal.
Don't be one of them.
Why Was Your Wegovy Denied?
Before you can fight a denial, you need to understand why it happened. Your denial letter should include a reason — if it doesn't, call your insurance and ask.
Here are the most common reasons Wegovy prior authorizations are denied:
1. "Not medically necessary"
The insurer doesn't believe you need Wegovy based on the documentation submitted. This often happens when:
- Your BMI wasn't clearly documented
- Weight-related comorbidities (diabetes, high blood pressure, sleep apnea) weren't mentioned
- The clinical notes didn't explain why Wegovy specifically is needed
Strengthen your documentation. Include detailed clinical notes, lab results showing weight-related conditions, and a letter from your provider explaining why Wegovy is medically necessary for you.
2. "Step therapy required"
Your insurer wants you to try a cheaper or older medication first (like Saxenda or Contrave) before approving Wegovy.
If you've already tried other weight loss approaches — diet, exercise, other medications — document that history. If there's a medical reason you can't take the required "step" medication, your provider can request an exception.
3. "Not on formulary"
Wegovy isn't on your plan's list of covered medications.
Request a "formulary exception." This asks the insurer to cover Wegovy even though it's not on their standard list. You'll need strong documentation of medical necessity.
4. "Weight loss plan exclusion"
Your employer's plan specifically excludes coverage for weight loss medications. This is common — only about 19% of large employer plans cover GLP-1 weight loss medications (as of 2024 data).
This is the hardest denial to overturn because it's a policy decision, not a medical one. However, there may be options: the cardiovascular pathway (if you have established heart disease), exception requests, or HR advocacy.
5. "Incomplete documentation"
The prior authorization was missing required information — lab results, BMI measurements, documentation of previous weight loss attempts, etc.
This is often the easiest to fix. Resubmit with complete documentation.
The Appeal Process: Step by Step
Your denial letter must include the specific reason for denial, instructions for how to appeal, and deadlines for filing (typically 60-180 days). If any of this is missing, call your insurance and request it.
Step 1: Gather supporting documentation
For a Wegovy appeal, you'll typically need:
- Medical records showing your BMI history
- Documentation of weight-related conditions (diabetes, hypertension, sleep apnea, high cholesterol)
- Records of previous weight loss attempts (diets, programs, medications)
- Lab results (A1c, lipid panel, liver function if relevant)
- A letter of medical necessity from your prescribing provider
Step 2: File an internal appeal
This is your first formal appeal, reviewed by your insurance company. Your provider can submit this on your behalf with a detailed appeal letter.
Step 3: Request a peer-to-peer review (optional)
Your provider can request a phone call with the insurance company's medical reviewer to discuss your case directly. This isn't a formal appeal, but it can help clarify the situation or identify what additional documentation is needed.
Step 4: If denied, file an external review
If your internal appeal fails, you have the right to an external review by an independent third party. This is required under the Affordable Care Act for most health plans. The external reviewer is not employed by your insurance company.
How PEAK Handles Denials Differently
At PEAK, we don't treat prior authorization as a checkbox to complete and forget. We treat it as an ongoing advocacy process.
We document thoroughly from the start. Our initial PA submissions include detailed clinical notes, documented BMI, comorbidities, and weight loss history. Many denials happen because the initial submission was incomplete — we aim to get it right the first time.
We appeal when appropriate. If your PA is denied, we review the reason, strengthen the documentation, and file an appeal. We don't assume a denial is final.
We do peer-to-peer reviews. Our providers are willing to get on the phone with insurance medical reviewers to advocate for your coverage.
We explore alternatives. If Wegovy is denied but Zepbound might be covered, we can pivot. If the cardiovascular indication applies to you, we can reframe the request. If self-pay becomes necessary, we'll help you find the best pricing.
What If Your Appeal Fails?
Sometimes, despite best efforts, insurance won't cover Wegovy. If that happens, you still have options:
Consider Zepbound. Different medications have different coverage. Your insurance may cover Zepbound even if it doesn't cover Wegovy.
Cardiovascular indication. If you have established cardiovascular disease (history of heart attack, stroke, or peripheral artery disease), Wegovy is FDA-approved to reduce cardiovascular risk. This may qualify for coverage even when weight loss is excluded.
Self-pay options. Novo Nordisk offers Wegovy through NovoCare Pharmacy at reduced prices, with cost varying by dose. This is significantly less than standard retail cash pricing.
Oral Wegovy. The FDA approved oral Wegovy (tablets) in December 2025. This may have different coverage than the injection, and self-pay pricing varies by plan and pharmacy.
Important safety information: Wegovy carries a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. It is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Discuss your full medical history with your clinician before starting treatment.
PEAK accepts commercial insurance and TRICARE. We do not accept Medicare or Medicaid, including Medicare Advantage and Medicaid managed care plans.
